公开(公告)号：US12115230B2

公开(公告)日：2024-10-15

申请号：US17918092

申请日：2021-04-09

Applicant: Verve Therapautics, Inc.

Inventor： Alexandra Chadwick ,  Kallanthottathil G. Rajeev ,  Ellen Rohde ,  Christopher Cheng ,  Caroline Reiss

IPC: C12N15/11 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/46 ,  A61K48/00 ,  C07K14/515 ,  C12N9/22 ,  C12N15/113 ,  C12N15/90

CPC classification number: A61K48/0066 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/465 ,  C07K14/515 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/907 ,  C07K2319/09 ,  C07K2319/80 ,  C12N2310/20 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/331 ,  C12N2310/335 ,  C12N2310/344 ,  C12N2310/3521 ,  C12N2800/80

Abstract: Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.

公开(公告)号：US20230340435A1

公开(公告)日：2023-10-26

申请号：US17918092

申请日：2021-04-09

Applicant: Verve Therapautics, Inc.

Inventor： Alexandra Chadwick ,  Kallanthottathil G. Rajeev ,  Ellen Rohde ,  Christopher Cheng ,  Caroline Reiss

IPC: C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  A61K38/46 ,  A61K31/7105

CPC classification number: C12N9/22 ,  A61K31/7105 ,  A61K38/465 ,  C12N15/11 ,  C12N15/907 ,  C07K2319/09 ,  C07K2319/80 ,  C12N2310/20 ,  C12N2310/321

Abstract: Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.